Galapagos NV
GLPG
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$31.13
Price+0.03%
$0.01
1Y
Price
Market Cap
$2.051b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-266.3%
EBITDA Margin-284.0%
Net Profit Margin-92.0%
Free Cash Flow MarginRevenue
$286.921m
+4.1%
1y CAGR+6.2%
3y CAGR-7.9%
5y CAGREarnings
-$435.955m
-688.5%
1y CAGR-185.5%
3y CAGR-157.5%
5y CAGREPS
-$6.75
-702.7%
1y CAGR+454.1%
3y CAGR+322.1%
5y CAGRBook Value
$2.875b
$4.126b
Assets$1.251b
Liabilities$8.815m
DebtDebt to Assets
0.2%
-
Debt to EBITDAFree Cash Flow
-$287.039m
+28.6%
1y CAGR+18.3%
3y CAGR+14.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company